A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

1436 GMT – Merck’s struggles with Gardasil aren’t easing up. The drug maker disclosed 1Q sales of the treatment, which prevents cancers caused from the human papillomavirus, declined 41% to ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

The drugmaker is still dealing with the fallout over its HPV vaccine Gardasil in China, where a drop in demand forced it to halt shipments and rescind its previous forecast of $11 billion in ...

Sales of WELIREG increased 63%, reaching $137 million. Vaccine portfolio performance included GARDASIL sales of $1.3 billion, impacted by a 40% decline in China due to elevated channel inventories.

In its rush to market its human papillomavirus vaccine, Merck forgot to make a strong and compelling case for compulsory immunization. Merck's human papillomavirus (HPV) vaccine Gardasil should ...

SEATTLE — Since its approval by the U.S. Food and Drug Administration in 2006, the HPV vaccine has made considerable strides in preventing cervical and oropharyngeal, or throat cancers.

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...